Editas Medicine (EDIT) Reports In-Line Q1 EPS

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.79), in-line with the analyst estimate of ($0.79). Revenue for the quarter came in at $9.9 million versus the consensus estimate of $3.29 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• BofA Securities Starts PhysicsWallah Ltd (PWL:IN) at Underperform
• DA Davidson Reiterates Buy Rating on Vulcan Materials Company (VMC)